At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
dasatinibdrug
Likely dose
dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis
In Brief
A Phase 2 clinical trial evaluating dasatinib for Scleroderma. Completed, enrolled 47 participants across 13 sites.
Detailed Summary
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScleroderma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartJan 2009
Primary CompletionJun 2010
Study CompletionApr 2011
TodayJul 2026
First PostedOct 2, 2008
Enrollment StartJan 1, 2009
Primary CompletionJun 1, 2010
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.8 years ago
Interventions
dasatinibdrug
Tablets, Oral, 100 mg, once daily, 6 months